E
Endo International PLC
LSE:0Y5F
Endo International PLC
LSE:0Y5F
Price:
926.8
USD
-0.1%
Market Closed
Market Cap:
$207.9B
Relative Value
There is not enough data to reliably calculate the relative value of 0Y5F.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
0Y5F
Relative Value
Base Case
Not Available
E
Multiples Across Competitors
0Y5F Competitors Multiples
Endo International PLC Competitors
Endo International PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
983.7B USD | 15.1 | 47.7 | 32.1 | 34.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.2B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
286.9B CHF | 4.7 | 30.6 | 12.9 | 15.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
233.3B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
241.3B CHF | 5.5 | 22.2 | 13.7 | 17.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
302B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.3 | 9.7 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.3B USD | 2.5 | 17.3 | 7.3 | 9 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
88.7B GBP | 2.7 | 15.5 | 7.8 | 11.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
